Altamira Therapeutics Ltd. · OTC:CYTOF

Altamira Therapeutics — IPO Roadshow (March 2023)

19 slides from Altamira Therapeutics's IPO roadshow presentation, Mar 8, 2023

  1. Slide 1: Delivering RNA – Beyond the Liver

    Slide 1: Delivering RNA – Beyond the Liver

    Investor Presentation Winter 2022/2023 DELIVERING RNA – BEYOND THE LIVER

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    2 NASDAQ: CYTO Forward - Looking Statements This press release may contain statements that constitute "forward - looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward - looking statements are statements oth

  3. Slide 3: Offering Summary

    Slide 3: Offering Summary

    3 NASDAQ: CYTO Offering Summary ISSUER Altamira Therapeutics Ltd. Listing / Symbol Nasdaq / CYTO Shares Offered Expected Price Range Expected Offering Size $8,000,000 Use of Proceeds • Research & Development • Working Capital and General Corporate Purposes • Repay $1M Debt Sole Book - Running Manage

  4. Slide 4: Company Overview

    Slide 4: Company Overview

    4 NASDAQ: CYTO Company Overview Disruptive, Proprietary RNA Delivery Technology Platform OligoPhore υ (siRNA) SemaPhore υ (mRNA) Platforms • Proprietary 21 amino acid peptide for efficient d elivery of RNA into target cells (nanoparticles) • Non - hepatic targets, unlike mainstream technology • Vali

  5. Slide 5: How Our Technology Works

    Slide 5: How Our Technology Works

    5 NASDAQ: CYTO How Our Technology Works OligoPhore υ /SemaPhore υ are nanoparticles comprising a proprietary peptide + RNA payload designed to enable safe and effective delivery by systemic administration. Stability RNA complexed in nanoparticle format and only released inside of cells after uptake

  6. Slide 6: RNA Delivery is One of the Key Challenges

    Slide 6: RNA Delivery is One of the Key Challenges

    6 NASDAQ: CYTO Exemplary listing of companies active in RNA therapeutics and delivery (list not exhaustive) RNA Delivery is One of the Key Challenges Silence gene expression Promote protein expression Deliver RNA therapeutic to target • Short interfering RNA (siRNA) • Antisense oligonucleotides (ASO

  7. Slide 7: Strong Growth – Only the Beginning

    Slide 7: Strong Growth – Only the Beginning

    7 NASDAQ: CYTO * Research and Markets ; Allied Market Research STRONG GROWTH — STARTING IN 2018 ONLY THE BEGINNING! 7 NASDAQ: CYTO mRNA Vaccines & Therapeutics Global Sales siRNA Therapeutics Global Sales $46.7B $101.3B $0B $20B $40B $60B $80B $100B $120B 2021 2026 Disruptive Technology Growth Oppor

  8. Slide 8: AM-401: Stop the Beating Heart of Tumors

    Slide 8: AM-401: Stop the Beating Heart of Tumors

    8 NASDAQ: CYTO 8 NASDAQ: CYTO AM - 401: Stop the “Beating Heart” of Tumors *KPC pancreatic tumor model in mice; Strand et al., 2019 Knock down various KRAS mutations with poly KRAS mut OligoPhore υ nanoparticles to inhibit cell proliferation in KRAS driven colorectal, pancreatic, or non small cell l

  9. Slide 9: AM-401 Key Differentiating Factors

    Slide 9: AM-401 Key Differentiating Factors

    AM - 401 KEY DIFFERENTIATING FACTORS 9 NASDAQ: CYTO KRAS driven cancer IND targeted for 2023 AM - 401 High unmet medical need – most aggressive tumors Multiple other small molecule inhibitors under development (G12C, G12D…), but few competing RNA projects (G12D or KRAS modulators) Small molecule G12

  10. Slide 10: AM-411: Block Inflammation in Rheumatoid Arthritis

    Slide 10: AM-411: Block Inflammation in Rheumatoid Arthritis

    10 NASDAQ: CYTO 10 NASDAQ: CYTO AM - 411: Block Inflammation in Rheumatoid Arthritis Knock down NF - κ B (p65), key checkpoint in RA inflammation. • Chronic autoimmune disease • Causes joint swelling and pain – Reduced QoL and productivity • Affects 1 out of 28 women / 59 men • No cure available, bu

  11. Slide 11: AM-411 Key Differentiating Factors

    Slide 11: AM-411 Key Differentiating Factors

    AM - 411 KEY DIFFERENTIATING FACTORS 11 NASDAQ: CYTO Rheumatoid arthritis IND targeted for 2024 AM - 411 Global rheumatoid arthritis market = $57.9 Billion in 2019 → $62.9 Billion in 2027 • Expiration of patents, biosimilars arriving • High hopes for novel Tx class of JAK inhibitors gave way to disa

  12. Slide 12: Corporate Strategy

    Slide 12: Corporate Strategy

    12 NASDAQ: CYTO Corporate Strategy OligoPhore υ has been tested in vivo … • Pancreatic and colorectal cancer (KRAS) • Ovarian cancer (TAM: AXL) • Lung cancer (ETV - 2) • Metastatic Melanoma (NF - κ B) • Adult T Cell Leukemia/Lymphoma (NF - κ B) • Sarcoma (MYCT - 1) • Necrotizing enterocolitis (NF -

  13. Slide 13: Intellectual Property

    Slide 13: Intellectual Property

    13 NASDAQ: CYTO Intellectual Property Compositions comprising a peptide - polynucleotide complex Methods for delivering such nanoplexes Coverage until 2034 (+ potential extension) Proprietary manufacturing process WORLDWIDE EXCLUSIVE LICENSE FROM WASHINGTON UNIVERSITY Patent covering OligoPhore υ /

  14. Slide 14: Capitalization Overview

    Slide 14: Capitalization Overview

    14 NASDAQ: CYTO Pro Forma Pre - Offering Common Shares 2,387,987 Convertible Note Conversion Shares and/or Pre - Funded Warrants* 1,932,402 Warrants (WAEP: $57.60) 99,171 Options (WAEP: $20.84) 157,730 Fully Diluted Shares Outstanding 4,577,290 Capitalization Overview * Represents the conversion of

  15. Slide 15: Management Overview

    Slide 15: Management Overview

    15 NASDAQ: CYTO Management Overview Thomas Meyer, PhD CEO & CHAIRMAN • Company founder • Funded and grew Company since 2003 • 14 years with Disetronic Group including CEO and BoD member (>20% sales CAGR, $3B market cap) Covadonga Pañeda , PhD CHIEF OPERATING OFFICER • Joined as CDO in 2022 • 18 year

  16. Slide 16: Investor Summary – RNA Business

    Slide 16: Investor Summary – RNA Business

    16 NASDAQ: CYTO Investor Summary – RNA Business Potential divestiture/partnering of Legacy Assets • Unlock intrinsic value • Source of non - dilutive funding RNA technology coming of age • Disruptive potential in human medicine • Rapidly growing # of RNA therapeutics Extensive proof of concept • Suc

  17. Slide 17: Contact

    Slide 17: Contact

    www.altamiratherapeutics.com Thomas Meyer CEO thm@altamiratherapeutics.com Covadonga Pañeda COO cop@altamiratherapeutics.com

  18. Slide 18: Legacy Programs to be Divested / Partnered

    Slide 18: Legacy Programs to be Divested / Partnered

    18 NASDAQ: CYTO Legacy Programs to be Divested / Partnered Bentrio ® Protection against airborne particles • Drug - free, preservative - free formulation, applied as nasal spray • Three clinical trials demonstrating safety and efficacy in allergic rhinitis • OTC product – Commercialized in selected

  19. Slide 19: Recent Developments

    Slide 19: Recent Developments

    19 NASDAQ: CYTO Recent Developments Clinical Study Demonstrates Bentrio’s Superior Nasal Residence Time and Rheological Properties • Bentrio ® remained detectable by fluorescence for up to 210 minutes in subjects' nasal passages vs. 60 minutes with saline nasal spra y control • Long nasal residence

Source: SEC EDGAR · FWP filed Mar 8, 2023

More decks from Altamira Therapeutics Ltd.

All 7 Altamira Therapeutics decks